Manganese enhanced magnetic resonance imaging in type 1 and type 2 diabetes mellitus

Abstract Background The pathophysiology of diabetic cardiomyopathy has yet to be established although pre-clinical studies suggest a role for altered myocardial calcium handling. Manganese-enhanced magnetic resonance imaging (MEMRI) is novel non-invasive method assessing in vivo Purpose To investigate whether handling impaired patients with either type 1 or 2 diabetes mellitus the absence underlying heart disease. Methods In prospective case-control study, (n=19) (n=10) and healthy volunteers (n=15) underwent MEMRI. Participants prior coronary artery disease, an abnormal electrocardiogram were excluded. Manganese dipyridoxyl diphosphate (0.1 mL/kg) was administered over 10 min T1 mapping performed every 2.5 30 after contrast infusion (Figure 1). Quantitative manganese uptake analysis by measuring relaxation times region interest within interventricular septum compared left ventricular blood pool. rate determined Patlak modelling [1]. Results older (50±13 55±15.3 years) than (32±10 years). All participants had preserved ejection fraction (type mellitus, 67.7±6.1%; 66.8±3.2%; volunteers, 65±3.5%). Mean reduced both (6.4±0.6 mL/100 g tissue/min) (6.4±0.5 (8.3±0.5 tissue/min; p<0.0001 both, Figure 2). There no differences between those (p=0.22). statistically significant correlation age study population (r=−0.28, p=0.07). Conclusion Using MEMRI, we have demonstrated that even systolic dysfunction. This suggests may underlie, contribute to, which implications developing therapeutic targets prevention treatment cardiomyopathy. Funding Acknowledgement Type funding sources: Other. Main source(s): British Heart Foundation - Clinical Research Training Fellowship (FS/CRTF/20/24087)AstraZeneca Investigator initiated award (ESR-19-20118)